An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

被引：50

作者：

Schey, SA ^{[1
]}

Cavenagh, J

Johnson, R

Child, JA

Oakervee, H

Jones, RW

机构：

[1] Univ London, Dept Hematol, Guys Hosp, Kings Coll London Med Sch, London SE1 9RT, England

[2] Barts & Royal London Hosp, Dept Haematol, London, England

[3] Birmingham Heartlands NHS Trust, Dept Haematol, Birmingham, W Midlands, England

[4] Gen Infirm, Dept Haematol, Leeds LS1 3EX, W Yorkshire, England

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 10期

关键词：

multiple myeloma; relapsed disease; thalidomide; treatment recommendations;

D O I：

10.1016/S0145-2126(03)00027-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myeloma remains incurable with conventional treatment in the vast majority of patients. The introduction of thalidomide in 1999 for the treatment of relapsed disease offers the opportunity to treat patients who have developed myelotoxicity or who are refractory to conventional chemotherapy. The optimal schedule remains unresolved and only two studies have reported long term follow-up data. We report a phase 11 low dose escalation study of thalidomide with long term follow-up showing overall survival (OS) of 19 months and progression free survival (PFS) of 14 months. In addition we report on the side effects and toxicity and give recommendations for the use of thalidomide in the relapsed setting based upon these findings. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：909 / 914

页数：6

共 27 条

[21] Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity [J].

Parman, T ;

Wiley, MJ ;

Wells, PG .

NATURE MEDICINE, 1999, 5 (05) :582-585

[22] Thalidomide - A revival story. [J].

Raje, N ;

Anderson, K .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1606-1609

[23] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[24]

UCHIYAMA H, 1993, BLOOD, V82, P3712

[25]

Vacca A, 1999, BLOOD, V93, P3064

[26] Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy [J].

Zangari, M ;

Siegel, E ;

Barlogie, B ;

Anaissie, E ;

Saghafifar, F ;

Fassas, A ;

Morris, C ;

Fink, L ;

Tricot, G .

BLOOD, 2002, 100 (04) :1168-1171

[27] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy [J].

Zangari, M ;

Anaissie, E ;

Barlogie, B ;

Badros, A ;

Desikan, R ;

Gopal, AV ;

Morris, C ;

Toor, A ;

Siegel, E ;

Fink, L ;

Tricot, G .

BLOOD, 2001, 98 (05) :1614-1615

← 1 2 3 →